Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online August 17, 2007
Diabetes 56:2715-2721, 2007
DOI: 10.2337/db06-1294
© 2007 by the American Diabetes Association
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db06-1294v1
db06-1294v2
56/11/2715    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wadham, C.
Right arrow Articles by Xia, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wadham, C.
Right arrow Articles by Xia, P.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

High Glucose Attenuates Protein S-Nitrosylation in Endothelial Cells

Role of Oxidative Stress

Carol Wadham1, Angela Parker1, Lijun Wang2, and Pu Xia1,2

1 Signal Transduction Laboratory, Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, Australia
2 Signal Transduction Laboratory, Centenary Institute, and Faculty of Medicine, the University of Sydney, Sydney, Australia

Address correspondence and reprint requests to Pu Xia, MD, Signal Transduction Laboratory, Centenary Institute, Locked Bag 6, Newtown, NSW 2042, Australia. E-mail: p.xia{at}centenary.org.au

Abbreviations: 4-OHCA, {alpha}-cyano-4-hydroxycinnamic acid; CCCP, carbonyl cyanide m-chlorophenyl hydrazone; DPI, diphenyleneiodonium; eNOS, endothelial nitric oxide synthase; FITC, fluorescein isothiocyanate; GSNO, nitrosylated glutathione; GSH, reduced glutathione; HEN, HEPES, EDTA, neocuproine; HUVEC, human umbilical vein endothelial cell; IKKß, inhibitory {kappa}B kinase-ß; mETC, mitochondrial electron transport chain; NF-{kappa}B, nuclear factor-{kappa}B; NOS, nitric oxide synthase; NOX, NAD(P)H oxidase; oxLDL, oxidized LDL; ROS, reactive oxygen species; TNF-{alpha}, tumor necrosis factor-{alpha}; TTFA, thenoyltrifluoroacetone


   ABSTRACT
TOP
 ABSTRACT
RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
OBJECTIVE—Hyperglycemia-induced endothelial dysfunction, via a defect of nitric oxide (NO) bioactivity and overproduction of superoxide, is regarded as one of the most significant events contributing to the vascular lesions associated with diabetes. However, the mechanisms underlying such hyperglycemic injury remain undefined. We hypothesized that alterations in cellular protein S-nitrosylation may contribute to hyperglycemia-induced endothelial dysfunction.

RESEARCH DESIGN AND METHODS—We exposed endothelial cells to high glucose in the presence and absence of reactive oxygen species inhibitors and used the biotin switch assay to analyze the alteration in the global pattern of protein S-nitrosylation compared with cells cultured under normal glucose conditions. We identified endogenous S-nitrosylated proteins by mass spectrometry and/or immunoblotting with specific antibodies.

RESULTS—High-glucose treatment induced a significant reduction of endogenous S-nitrosylated proteins that include endothelial NO synthase, ß-actin, vinculin, diacylglycerol kinase-{alpha}, GRP78, extracellular signal–regulated kinase 1, and transcription factor nuclear factor-{kappa}B (NF-{kappa}B). Interestingly, these changes were completely reversed by inhibition of superoxide production, suggesting a key role for oxidative stress in the regulation of S-nitrosylation under hyperglycemic conditions. In addition, we found that in parallel with the restoration of decreased S-nitrosylation of NF-{kappa}B, high glucose–induced NF-{kappa}B activation was blocked by the superoxide inhibitors.

CONCLUSIONS—The alterations in protein S-nitrosylation may underlie the adverse effect of hyperglycemia on the vasculature, such as endothelial dysfunction and the development of diabetic vascular complications.

Hyperglycemia is now well recognized as a major etiological factor causing both micro- and macrovascular lesions associated with diabetes (1,2). A series of interconnected biochemical changes initiated by hyperglycemia have been documented to directly affect cellular function resulting in abnormal vascular remodeling and the development of diabetic complications (3,4). Endothelial dysfunction, characterized by a loss of nitric oxide (NO) bioactivity via increased superoxide production, is regarded as one of the most important cellular events accounting for the adverse effects of high glucose on the vasculature (4).

NO is constitutively expressed by endothelial cells, serving as a pivotal endothelium-derived modulator that maintains normal function of the vasculature through its vasodilator, antiplatelet, antiproliferative, antioxidant, and anti-inflammatory properties. A decline in NO bioactivity and the resultant endothelial dysfunction occurs in many disease settings, including hyperlipidemia, hypertension, metabolic syndrome, and diabetes (rev. in 5). Substantial evidence exists from both in vitro and in vivo studies showing that exposure to hyperglycemia reduces endothelial NO availability and its bioactivity (6,7). High glucose–induced NO deficiency is partially attributable to the uncoupling of the endothelial NO synthase (eNOS) reaction resulting in the net synthesis of superoxide and to the oxidative inactivation of NO (8). However, the downstream signaling events augmented by the reduction of NO bioavailability under high-glucose conditions remain largely unexplored.

The interaction of NO with heme-containing proteins (such as in guanylyl cyclase) is the most recognized signaling event associated with NO, whereas it is also increasingly apparent that nitrosylation of protein sulfhydryl groups represents an important additional NO-dependent signaling mechanism (9). To date, >100 proteins with a broad functional spectrum have been identified as targets for S-nitrosylation (10). S-nitrosylation, entailing the transfer of nitrosonium to reduced cysteine residue, has been documented to regulate the activity of a number of metabolic enzymes, proteases, protein kinases/phosphatases, receptors, and transcription factors, together with various cytoskeletal and structural components (10). It has been reported that S-nitrosylation of proteins in endothelial cells occurs under various physiological or pathophysiological conditions and plays an important role in the regulation of endothelial function (11). For instance, treatment with the pro-inflammatory cytokine tumor necrosis factor-{alpha} (TNF-{alpha}) or oxidized LDL (oxLDL) resulted in a decrease in endothelial protein S-nitrosylation (12). Exposure to shear stress, which is vasoprotective, resulted in a global increase in protein S-nitrosylation in endothelial cells (13).

Despite current knowledge that a decline in NO bioactivity accounts for the effect of high glucose on endothelial dysfunction and vascular injury associated with diabetes, the molecular mechanisms underlying such events remain undefined. The studies described herein were undertaken to examine whether S-nitrosylation of proteins is affected by high glucose in endothelial cells, together with an examination of potential mechanisms involved in the regulation of protein S-nitrosylation under such conditions.


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell culture and reagents.
Reagents not otherwise indicated were from Sigma (St. Louis, MO). Human umbilical vein endothelial cells (HUVECs) were isolated and cultured as described previously (14). Cells were used at passages 2 to 3. The cells were grown in M199 supplemented with 20% FCS and endothelial growth factors. For the experimental studies, HUVECs were allowed to reach confluence in the regular growth medium and then cultured for 3 days in 1) medium containing 5.5 mmol/l glucose (referred to as normal glucose); 2) normal glucose medium supplemented with additional glucose to final concentration of 30 mmol/l (high glucose); or 3) normal glucose medium containing 24.5 mmol/l mannitol. For experiments including reactive oxygen species (ROS) inhibitors, the cells were incubated overnight with the NAD(P)H oxidase (NOX) inhibitor apocynin (500 µmol/l); NOX and NO synthase (NOS) inhibitor diphenyleneiodonium (DPI) (10 µmol/l); superoxide dismutase mimetic TEMPOL (1 mmol/l); or the mitochondrial electron transport chain (mETC) inhibitors carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (500 nmol/l), thenoyltrifluoroacetone (TTFA) (10 µmol/l), or {alpha}-cyano-4-hydroxycinnamic acid (4-OHCA) (250 µmol/l) and compared with DMSO-treated control. All ROS inhibitors were dissolved in DMSO and diluted 1:1,000 in culture medium when added to the cells. In some experiments, the cell extracts were incubated with 100 µmol/l reduced glutathione (GSH) or nitrosylated glutathione (GSNO) 100 µmol/l for 20 min at room temperature in the dark.

Detection of S-nitrosylated proteins by the biotin switch assay.
The biotin switch assay was performed essentially as described by Jaffrey and Snyder (15) with some modifications. After treatment, cells were lysed in HEN buffer (250 mmol/l HEPES, pH 7.7, 1 mmol/l EDTA, and 0.1 mmol/l neocuproine) containing 0.1% SDS. Cellular extracts were adjusted to below 0.8 mg/ml protein, and equal amounts were incubated with 4 volumes HEN buffer containing 2.5% SDS and 20 mmol/l S-methyl methanethiosulfonate at 50°C for 20 min with frequent agitation to block free thiols. After blocking, extracts were precipitated with 4 volumes cold (–20°C) acetone, dried at room temperature, and resuspended in 100 µl HENS buffer (HEN plus 1% SDS) adjusted to pH 6.8 to prevent the biotinylation of primary amines. Until this point, all steps were carried out in the dark. S-nitrosothiols were decomposed by adding 5 mmol/l ascorbate followed by incubation with 2 mmol/l biotin-BMCC (Pierce, Rockford, IL) or vehicle alone for 2 h at room temperature. Proteins were then precipitated again using acetone and resuspended in HENS buffer. For purification of biotinylated proteins, samples were diluted with 2 volumes neutralization buffer (20 mmol/l HEPES, pH 7.7, 100 mmol/l NaCl, 1 mmol/l EDTA, and 0.5% Triton X-100) and 25 µl 50% streptavidin agarose suspension (Sigma) and incubated for 1 h at room temperature with agitation. Beads were washed four times with neutralization buffer. Proteins were eluted by boiling in reducing sample buffer for 5 min, separated on 10% SDS-PAGE gels, transferred to polyvinylidine fluoride, and blotted with specific antibodies, including anti-biotin (Sigma), anti-actin (Chemicon, Temecula, CA), anti-vinculin (Chemicon), anti-talin (Upstate Biotechnology, Lake Placid, NY), anti-vimentin (Promega, Madison, WI), and anti-p50 nuclear factor-{kappa}B (NF-{kappa}B) (Upstate Biotechnology), respectively, developed using horseradish peroxidase–conjugated secondary antibody (Abcam, Cambridge, U.K.) and enhanced chemiluminescence (Amersham Pharmacia Biotech). Band intensities in the blots were analyzed by densitometry using an ImageQuant program (Molecular Dynamics) and normalized to control bands.

Immunostaining of S-nitrosylated proteins.
Cells were incubated with 5.5 or 30 mmol/l glucose for 3 days and fixed with 4% paraformaldehyde for 15 min at room temperature. After permeabilization and blocking (permeabilization solution: 3% BSA fraction V, 0.3% Triton X-100, 5% horse serum in PBS), cells were incubated with anti-nitrosocysteine antibody (1:50) overnight at 4°C. After incubation with a biotin-conjugated anti-rabbit antibody (1:500), cells were labeled with streptavidin-fluorescein and visualized by fluorescence microscopy (magnification 1:40). Serving as a negative control, fixed and permeabilized cells were preincubated with 0.8% HgCl2 for 1 h at 37°C as described previously (12).

Mass spectrometry analysis.
Mass spectrometry analysis was conducted in the Hanson Institute Protein Core Facility (Adelaide, Australia). Protein samples that had been subjected to the biotin switch assay were excised from Coomassie blue–stained gels and digested with trypsin, and the resulting peptides were desalted into an electrospray-ionization quadrupole/time-of-flight mass spectrometer (Q-TOF2; Micromass, Manchester, U.K.) through a C18 reverse-phase silica column. Automated mass spectrometry analysis sequencing was carried out using data-directed analysis techniques. The data were then analyzed by using ProteinLynx Global Server 2.2 to determine possible sequence tags from fragmented ions, and the SwissProt protein database searched for possible matches.

Fluorescence in situ DNA binding assay for detecting NF-{kappa}B activation.
After high-glucose treatment, HUVECs were seeded onto fibronectin coated eight-well chamber slides and cultured under the same conditions overnight in the presence or absence of the ROS inhibitors. Serving a positive control for NF-{kappa}B activation, cells were stimulated with 10 ng/ml TNF-{alpha} for 20 min. The cells were washed one time with PBS and then fixed with 4% paraformaldehyde. The assays were performed essentially as described by Kurose et al. (16) with the following modifications. Fluorescein isothiocyanate (FITC)-labeled oligodeoxynucleotides (Geneworks, Thebarton, Australia), including the NF-{kappa}B binding site of the E-selectin gene (FITC-5'CTTTACTGCATGTCCAGGATGCCATTGGGGATTTCCTCTG-3') was used to detect DNA binding activity. FITC-5' CTTTACTGCATGTCCAGGATGCCATTGAGCTATCTCACTG-3' was used as a negative control. Epifluorescence microscopy was performed on an Olympus BX-51 microscope equipped with excitation filters for fluorescein (494 nm), attached to a Cool Snap FX, charge-coupled device camera (Photometrics, Phoenix, AZ). Images were adjusted for brightness and contrast with V++ software (Digital Optics, Auckland, New Zealand).

Statistical analysis.
Data are expressed as means ± SE. One-way ANOVA and unpaired Student’s t tests were used for comparison between groups. A value of P < 0.05 was considered statistically significant.


   RESULTS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
High glucose reduces the S-nitrosylated protein content in HUVECs.
To assess the effect of high glucose on protein S-nitrosylation, we incubated endothelial cells with 5.5 or 30 mmol/l glucose for 3 days, because this represents a useful model for the study of hyperglycemic injury on the endothelium (14). By using the biotin switch assay as described by Jaffrey and Snyder (15), we were able to detect significant amounts of S-nitrosylated proteins in HUVECs under normal culture conditions (Fig. 1A), which is consistent with previous reports showing a considerable basal level of protein S-nitrosylation in endothelial cells (12,13). Interestingly, exposure of HUVECs to high glucose for 3 days resulted in an overall decrease in the levels of S-nitrosylated proteins compared with the cells cultured under normal glucose conditions. Similar results were obtained when cells were cultured under high-glucose conditions for up to 1 week (data not shown). The high glucose–induced reduction of protein S-nitrosylation was further confirmed by immunostaining with anti–S-nitrosocysteine antibodies, as shown in Fig. 1B. However, there was no significant change in the content of S-nitrosylated proteins when cells were exposed to high glucose for <48 h (data not shown), indicating a chronic effect of high glucose. Serving as a control, HUVECs cultured with mannitol at 30 mmol/l had no effect on the protein S-nitrosylation (data not shown), ruling out a possible influence of osmotic stress.


Figure 1
View larger version (36K):
[in this window]
[in a new window]

  		FIG. 1. Effect of high glucose on protein S-nitrosylation in HUVECs. HUVECs were exposed to 5.5 (NG) or 30 mmol/l (HG) glucose for 3 days. A: Whole-cell lysates were subjected to the biotin switch assay as described in RESEARCH DESIGN AND METHODS. S-nitrosylated proteins were separated by SDS-PAGE and immunoblotted with anti-biotin antibodies. The bottom immunoblot was conducted with whole-cell lysates and probed with anti-vinculin antibodies, showing an equal level of protein loading. B: Treated cells were fixed and immunostained with anti-nitrosocysteine antibodies as described in RESEARCH DESIGN AND METHODS. Data are representative of similar results in at least three separate experiments with different primary HUVEC lines.

 
Effect of GSNO on high glucose–induced reduction of protein S-nitrosylation.
The effect of hyperglycemia has been well documented to decrease endothelial NO production or its availability (6,7). We therefore examined whether the decreased protein S-nitrosylation could be restored in a cell-free system by treatment of the cell lysates with a physiological trans-nitrosylating agent, GSNO. We found that incubation with the NO donor GSNO mildly increased the overall level of S-nitrosylation in cell extracts derived from either normal glucose–or high glucose–treated HUVECs (Fig. 2). Serving as a control, GSH has no effect on protein S-nitrosylation, and therefore the result reflects the level of endogenous S-nitrosylation. Interestingly, after the incubation with GSNO, the high glucose–induced reduction of S-nitrosylated proteins was not restored to the control levels (Fig. 2), suggesting that the low level of NO availability is not the only cause of reduced endogenous protein S-nitrosylation under high-glucose conditions.


Figure 2
View larger version (64K):
[in this window]
[in a new window]

  		FIG. 2. Effect of GSNO on protein S-nitrosylation. Lysates from HUVECs treated as described in Fig. 1 were incubated with 100 µmol/l GSNO or GSH for 20 min at room temperature in the dark and then subjected to the biotin switch assay. S-nitrosylated proteins were separated by SDS-PAGE and immunoblotted with anti-biotin antibodies. The bottom immunoblot of whole-cell lysates was blotted with anti-actin antibodies, showing an equal level of protein loading. A representative Western blot is shown from at least three separate experiments with different primary HUVEC lines.

 
Characterization of high glucose–induced reduction of S-nitrosylated proteins.
To characterize the reduced S-nitrosylated proteins by high glucose, we performed a purification of the S-nitrosylated proteins using the biotin switch method followed by proteomic analysis. Two proteins were identified by mass spectrometry analysis: GRP78 and ß-actin. Because numerous proteins have been reported as targets for S-nitrosylation, we then examined the effect of high glucose on known S-nitrosylated proteins by a series of Western blot assays. Endogenous S-nitrosylated proteins were precipitated from HUVECs exposed to 5.5 or 30 mmol/l glucose for 3 days by the biotin switch method and then detected by individual immunoblotting assays. As shown in Table 1, a total of 10 S-nitrosylated proteins were identified. Seven proteins showed significant reductions in their S-nitrosylation status after high-glucose treatment.


View this table:
[in this window]
[in a new window]

  		TABLE 1 Identification of S-nitrosylated proteins in high glucose–treated cells

 
ROS inhibitors reverse the effect of high glucose on S-nitrosylation.
Oxidative stress arising chiefly from ROS production is thought to underlie many of the deleterious effects of high glucose on the vasculature in diabetes (4). We therefore addressed whether the high glucose–induced overproduction of ROS is affecting the level of S-nitrosylation. To this end, we treated endothelial cells with various inhibitors of NOX and NOS, which are believed to be chiefly responsible for ROS production under high-glucose conditions (rev. in 17). As shown in Fig. 3A, in the presence of the NOX and NOS inhibitor DPI, high glucose–induced reduction of global protein S-nitrosylation was restored to a level approaching that observed in control cells. The same results were obtained with the NOX inhibitor apocynin and the superoxide scavenger TEMPOL (data not shown). In addition, the tricarboxylic acid cycle has also been identified as a major source of ROS induced by high glucose, because blocking of mETC by various inhibitors is capable of preventing the high glucose–induced ROS production (18). Interestingly, the mETC inhibitors CCCP, 4-OHCA, and TTFA have similar effects to that of the NOX and/or NOS inhibitors to completely restore the decreased levels of S-nitrosylation in high glucose–treated cells (Fig. 3B). Taken together, these results suggest a key role for ROS in mediating high glucose–induced reduction of protein S-nitrosylation in endothelial cells.


Figure 3
View larger version (45K):
[in this window]
[in a new window]

  		FIG. 3. Effect of ROS inhibitor on S-nitrosylation in HUVECs. A and B: After a 3-day incubation with normal (NG) or high glucose (HG) and treatment with 10 µmol/l DPI (A) or 500 nmol/l CCCP, 10 µmol/l TTFA, or 4-OHCA (B) for 16 h, cell lysates were then subjected to the biotin switch assay and immunoblot analysis with anti-biotin antibodies. Anti-vimentin antibodies were used to control for loading. Data are representative of similar results in at least three separate experiments with different primary HUVEC lines.

 
Effect of high glucose on NF-{kappa}B S-nitrosylation and activation.
We and others have previously reported that high glucose was able to activate the transcription factor NF-{kappa}B (14,18), whereas NO has been shown to inhibit (19) NF-{kappa}B activation through S-nitrosylation (20,21). Therefore, we sought to examine whether high glucose–induced activation of NF-{kappa}B is due to a reduction of S-nitrosylation. Under normal culture conditions, NF-{kappa}B was S-nitrosylated in HUVECs (Fig. 4A). After incubation of the cell extracts with GSNO, the level of S-nitrosylation was mildly increased. By contrast, endogenous S-nitrosylation of NF-{kappa}B was barely detectable in cells exposed to high glucose. Although GSNO increased the extent of S-nitrosylation, it failed to restore NF-{kappa}B S-nitrosylation to that seen in control cells. Similar to the high glucose–induced reduction of overall protein S-nitrosylation, the decreased NF-{kappa}B S-nitrosylation was also completely reversed through treatment with the mETC inhibitors, either TTFA or CCCP or 4-OHCA (Fig. 4B). Consequently, the high glucose–induced increase in NF-{kappa}B activity, as measured by a fluorescence in situ DNA binding assay, was completely inhibited by the mETC inhibitors (Fig. 4C), which is consistent with a previous report by Nishikawa et al. (18). These observations suggest that high glucose activates NF-{kappa}B by inducing ROS production and the resultant inhibition of NF-{kappa}B S-nitrosylation.


Figure 4
View larger version (53K):
[in this window]
[in a new window]

  		FIG. 4. Effect of high glucose on S-nitrosylation and activation of NF-{kappa}B. A: Cell lysates derived from HUVECs exposed to normal (NG) or high glucose (HG) for 3 days were incubated with GSH or GSNO and then subjected to the biotin switch assay as described in RESEARCH DESIGN AND METHODS. Streptavidin-agarose purified S-nitrosylated proteins, along with 20 µl lysates, were separated by SDS-PAGE and immunoblotted with anti–NF-{kappa}B antibodies. The equal expression levels of NF-{kappa}B were shown in the immunoblot of the original lysates (left two lanes). B: HUVECs were incubated with NG or HG for 3 days and treated with 500 nmol/l CCCP, 10 µmol/l TTFA, or 4-OHCA for 16 h, and the level of S-nitrosylated NF-{kappa}B was then determined by the biotin switch assay. Results are representative of three independent experiments on different primary cell lines of HUVECs. A combined densitometric analysis is shown in the bottom panel. *P < 0.05, HG vs. NG; **P < 0.05, ROS inhibitor–treated vs. HG alone. C: NG- or HG-treated cells were treated with CCCP or TTFA, and NF-{kappa}B activity was then measured by fluorescence in situ DNA binding assay as described in RESEARCH DESIGN AND METHODS. The NF-{kappa}B reactive oligonucleotide fluorescence was not found in HUVECs cultured with NG, whereas the fluorescence accumulated in the nuclei of cells exposed to HG and detected by epifluorescence microscopy. Phase-contrast micrographs are shown in the left panel. Data are representative of similar results in at least three separate experiments with different primary HUVEC lines.

 

   DISCUSSION
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In the present study, we report for the first time, to our knowledge, that high glucose was able to attenuate the overall level of protein S-nitrosylation in primary human endothelial cells. We have identified at least seven proteins that were reduced by high glucose in their S-nitrosylation status as shown in Fig. 1 and Table 1. These decreased S-nitrosylated proteins can be classed as 1) cytoskeleton proteins (ß-actin, paxillin, vimentin, and vinculin), 2) metabolic enzymes (eNOS and diacylglycerol kinase-{alpha}), 3) chaperone (GRP78), 4) signaling molecules (H-ras and ERK-1), and 5) transcription factor (NF-{kappa}B). It is noted that although the level of a vast majority of S-nitrosylated proteins was decreased, the extent of a number of them was actually either increased or unchanged under high-glucose conditions, suggesting a specific role for high glucose in the regulation of protein S-nitrosylation. Because S-nitrosylation has been implicated in the regulation of numerous protein activities (10), the findings that high glucose regulates protein S-nitrosylation in endothelial cells could provide a new insight into the mechanisms underlying hyperglycemic injury on the vasculature.

More than 100 individual proteins have been identified as targets for S-nitrosylation, while the mechanisms underlying regulation of S-nitrosylation are still unclear. The extent of protein S-nitrosylation in endothelial cells decreases after exposure to the pro-inflammatory mediators TNF and oxLDL (12) and increases in cells under shear stress (13). TNF and oxLDL induce superoxide release in endothelial cells (5), whereas shear stress reduces oxidative stress by increasing the expression of antioxidant molecules, such as superoxide dismutase, and raising the intracellular levels of glutathione and NO (22). S-nitrosylation of any given target protein is thought to be influenced by the rate of formation of biologically relevant nitrosylating species, or the rate of denitrosylation (9). High glucose is known to reduce the bioavailability of NO in the cell, so the decreased S-nitrosylation may have been caused by limited availability of nitrosylating species. However, although incubation with GSNO increased the overall level of protein S-nitrosylation, the reduced S-nitrosylation in high glucose–treated cells was not restored to the level detected in the control cells after GSNO incubation in vitro. This indicated that decreased S-nitrosylation was not solely due to limiting NO availability in endothelial cells. Whether the rate of denitrosylation is enhanced by high glucose and thus accounts for the decreased protein S-nitrosylation needs further investigation.

One of the most important findings reported herein is that the inhibitory effect of high glucose on protein S-nitrosylation was completely abrogated by inhibiting ROS generation. Multiple lines of evidence have shown that the overproduction of superoxide under high-glucose conditions, in particular by mitochondria that have been uncoupled by the flux of NADH from the excess glycolysis, results in an inhibition of glyceraldehyde-3-phosphate dehydrogenase and subsequent accumulation of glycolysis intermediates (23). It has been reported that inhibition of ROS production prevented the high glucose–induced activation of aldose reductase and hexosamine pathways, PKC activation, and formation of advanced glycosylation end products (18). Furthermore, treatment of streptotozin-induced diabetic rats with the antioxidant N-acetylcysteine prevented the diabetes-associated defects in endothelium-dependent relaxation (24). Therefore, oxidative stress has been proposed as a unifying mechanism responsible for the initiation of hyperglycemia-associated endothelial dysfunction and vascular injury. ROS can affect many signaling pathways, such as G-proteins, protein kinases, ion channels, and transcription factors, including NF-{kappa}B (25). Enhanced oxidative stress can also interfere with the availability of NO.

We found that the high glucose–induced reduction of protein S-nitrosylation was reversed in the cells treated with either nonspecific antioxidants, including apocynin, DPI, and the superoxide scavenger TEMPOL, or with the mETC-specific inhibitors TTFA, CCCP, or 4-OHCA, which have been previously shown to completely block ROS formation in endothelial cells under high-glucose conditions (18). Although to some degree, variations were observed among these different ROS inhibitors (Figs. 3 and 4), they are able to profoundly prevent high glucose–induced reduction of protein S-nitrosylation, suggesting a causal role for ROS. It has been recently demonstrated that superoxide was able to induce decomposition of S-nitrosothiols in a dose- and time-dependent manner (26). In addition, among the various S-nitrosylated proteins, the majority are reportedly regulated at a single critical cysteine residue within an acid-base or hydrophobic structural motif, which could also be subject to oxygen- or glutathione-dependent modification (9), suggesting a possible role for superoxide in the regulation of S-nitrosylation. On the other hand, NO has also been suggested to regulate the activity of thioredoxin, a key endogenous antioxidant, through S-nitrosylation on Cys69, representing a counterpoising connection between these two important gaseous signaling pathways. Interestingly, Schulze et al. (27) reported that NO also suppresses mRNA expression of the thioredoxin inhibitory protein Txnip in vascular smooth muscle cells via a NO-responsive cis-regulatory element in the Txnip promoter, an effect that is abrogated by high glucose, suggesting an additional molecular mechanism whereby high glucose induces endothelial dysfunction.

NF-{kappa}B is a master transcription factor that regulates a number of genes that are critically involved in the regulation of endothelial function and the pathogenesis of various vascular disorders. Hyperglycemia has been reported to activate NF-{kappa}B through activation of protein kinase C (19) and the sphingosine kinase (14) pathways or via overproduction of ROS (18). By contrast, NO is a potent inhibitor of NF-{kappa}B activation (28). Interestingly, inhibitory {kappa}B kinase-ß (IKKß), the catalytic subunit required for the activation of NF-{kappa}B, has been demonstrated as a direct target of S-nitrosylation, resulting in loss of IKKß activity (21). Additionally, the p50 subunit of NF-{kappa}B has been also reported to be S-nitrosylated, causing an inhibition of its binding to DNA (20). Thus, NO is capable of acting at multiple points along the pathway to attenuate NF-{kappa}B signaling through S-nitrosylation. We found that the NF-{kappa}B S-nitrosylation was significantly decreased in the high glucose–treated endothelial cells and that this reduction was completely reversed by inhibition of ROS generation. Consequently, the high glucose–induced inhibition of NF-{kappa}B activity was blocked by the ROS inhibitors (Fig. 4). These observations suggest that the decreased S-nitrosylation of NF-{kappa}B may play a role in the oxidative stress-mediated NF-{kappa}B activation in endothelial cells under high-glucose conditions.

In conclusion, we have shown that high glucose dramatically alters the global pattern of protein S-nitrosylation along with a significant reduction of the S-nitrosylated proteins in endothelial cells. The effect of high glucose was prevented by ROS inhibitors, suggesting that oxidative stress may either prevent S-nitrosylation or accelerate denitrosylation. Although the direct functional consequences of such alteration in S-nitrosylation of specific proteins remain to be identified, the changes in S-nitrosylation may contribute to hyperglycemia-induced endothelial dysfunction and vascular lesions. This finding could pave a new way to designing new strategies for prevention and treatment of diabetes-associated cardiovascular diseases.


   ACKNOWLEDGMENTS
 
C.W. has received grants from the National Heart Foundation of Australia. P.X. has received a Career Development Fellowship and grants from the National Heart Foundation of Australia.

We thank Drs. C.J. Bagley and I. Milne for performing the mass spectrometry analysis, Dr. J.R. Gamble for providing HUVECs, and Dr. A. Holmes for reading the manuscript.


   FOOTNOTES
 
Published ahead of print at http://diabetes.diabetesjournals.org on 17 August 2007. DOI: 10.2337/db06-1294.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received for publication September 13, 2006 and accepted in revised form August 12, 2007


   REFERENCES
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986, 1993[Abstract/Free Full Text]
  2. U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853, 1998[Medline]
  3. King GL, Kunisaki M, Nishio Y, Inoguchi T, Shiba T, Xia P: Biochemical and molecular mechanisms in the development of diabetic vascular complications. Diabetes 45 (Suppl. 3):S105–S108, 1996
  4. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820, 2001[Medline]
  5. Mueller CF, Laude K, McNally JS, Harrison DG: ATVB in focus: redox mechanisms in blood vessels. Arterioscler Thromb Vasc Biol 25:274–278, 2005[Abstract/Free Full Text]
  6. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA: Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97:1695–1701, 1998[Abstract/Free Full Text]
  7. Veves A, Akbari CM, Primavera J, Donaghue VM, Zacharoulis D, Chrzan JS, DeGirolami U, LoGerfo FW, Freeman R: Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 47:457–463, 1998[Abstract]
  8. Hayden MR, Tyagi SC: Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol 2:2, 2003[Medline]
  9. Stamler JS, Lamas S, Fang FC: Nitrosylation: the prototypic redox-based signaling mechanism. Cell 106:675–683, 2001[Medline]
  10. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS: Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 6:150–166, 2005[Medline]
  11. Martinez-Ruiz A, Lamas S: Detection and proteomic identification of S-nitrosylated proteins in endothelial cells. Arch Biochem Biophys 423:192–199, 2004[Medline]
  12. Hoffmann J, Haendeler J, Zeiher AM, Dimmeler S: TNFalpha and oxLDL reduce protein S-nitrosylation in endothelial cells. J Biol Chem 276:41383–41387, 2001[Abstract/Free Full Text]
  13. Hoffmann J, Dimmeler S, Haendeler J: Shear stress increases the amount of S-nitrosylated molecules in endothelial cells: important role for signal transduction. FEBS Lett 551:153–158, 2003[Medline]
  14. Wang L, Xing XP, Holmes A, Wadham C, Gamble JR, Vadas MA, Xia P: Activation of the sphingosine kinase-signaling pathway by high glucose mediates the proinflammatory phenotype of endothelial cells. Circ Res 97:891–899, 2005[Abstract/Free Full Text]
  15. Jaffrey SR, Snyder SH: The biotin switch method for the detection of S-nitrosylated proteins. Sci STKE 2001:L1, 2001
  16. Kurose I, Saito H, Miura S, Ebinuma H, Higuchi H, Watanabe N, Zeki S, Nakamura T, Takaishi M, Ishii H: CD18/ICAM-1-dependent oxidative NF-kappaB activation leading to nitric oxide production in rat Kupffer cells cocultured with syngeneic hepatoma cells. J Clin Invest 99:867–878, 1997[Medline]
  17. Wassmann S, Wassmann K, Nickenig G: Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension 44:381–386, 2004[Abstract/Free Full Text]
  18. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787–790, 2000[Medline]
  19. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C, Remuzzi G: Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest 101:1905–1915, 1998[Medline]
  20. Marshall HE, Stamler JS: Inhibition of NF-kappa B by S-nitrosylation. Biochemistry 40:1688–1693, 2001[Medline]
  21. Reynaert NL, Ckless K, Korn SH, Vos N, Guala AS, Wouters EF, van der Vliet A, Janssen-Heininger YM: Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc Natl Acad Sci U S A 101:8945–8950, 2004[Abstract/Free Full Text]
  22. Gimbrone MA Jr, Topper JN, Nagel T, Anderson KR, Garcia-Cardena G: Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci 902:230–239, 2000[Abstract/Free Full Text]
  23. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, Tilton RG: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42:801–813, 1993[Abstract]
  24. Pieper GM, Siebeneich W: Oral administration of the antioxidant, N-acetylcysteine, abrogates diabetes-induced endothelial dysfunction. J Cardiovasc Pharmacol 32:101–105, 1998[Medline]
  25. Madamanchi NR, Vendrov A, Runge MS: Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 25:29–38, 2005[Abstract/Free Full Text]
  26. Aleryani S, Milo E, Rose Y, Kostka P: Superoxide-mediated decomposition of biological S-nitrosothiols. J Biol Chem 273:6041–6045, 1998[Abstract/Free Full Text]
  27. Schulze PC, Liu H, Choe E, Yoshioka J, Shalev A, Bloch KD, Lee RT: Nitric oxide-dependent suppression of thioredoxin-interacting protein expression enhances thioredoxin activity. Arterioscler Thromb Vasc Biol 26:2666–2672, 2006[Abstract/Free Full Text]
  28. Janssen-Heininger YM, Poynter ME, Baeuerle PA: Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radic Biol Med 28:1317–1327, 2000[Medline]
  29. Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH: Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell Biol 3:193–197, 2001[Medline]
  30. Verrier E, Wang L, Wadham C, Albanese N, Hahn C, Gamble JR, Chatterjee VK, Vadas MA, Xia P: PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase. Circ Res 94:1515–1522, 2004[Abstract/Free Full Text]
  31. Ravi K, Brennan LA, Levic S, Ross PA, Black SM: S-nitrosylation of endothelial nitric oxide synthase is associated with monomerization and decreased enzyme activity. Proc Natl Acad Sci U S A 101:2619–2624, 2004[Abstract/Free Full Text]
  32. Hao G, Derakhshan B, Shi L, Campagne F, Gross SS: SNOSID, a proteomic method for identification of cysteine S-nitrosylation sites in complex protein mixtures. Proc Natl Acad Sci U S A 103:1012–1017, 2006[Abstract/Free Full Text]
  33. Dall’Agnol M, Bernstein C, Bernstein H, Garewal H, Payne CM: Identification of S-nitrosylated proteins after chronic exposure of colon epithelial cells to deoxycholate. Proteomics 6:1654–1662, 2006[Medline]
  34. Mallis RJ, Buss JE, Thomas JA: Oxidative modification of H-ras: S-thiolation and S-nitrosylation of reactive cysteines. Biochem J 355:145–153, 2001[Medline]
  35. Yang Y, Loscalzo J: S-nitrosoprotein formation and localization in endothelial cells. Proc Natl Acad Sci U S A 102:117–122, 2005[Abstract/Free Full Text]
  36. Greco TM, Hodara R, Parastatidis I, Heijnen HF, Dennehy MK, Liebler DC, Ischiropoulos H: Identification of S-nitrosylation motifs by site-specific mapping of the S-nitrosocysteine proteome in human vascular smooth muscle cells. Proc Natl Acad Sci U S A 103:7420–7425, 2006[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db06-1294v1
db06-1294v2
56/11/2715    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wadham, C.
Right arrow Articles by Xia, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wadham, C.
Right arrow Articles by Xia, P.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum